GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Ending Cash Position

Cantargia AB (OSTO:CANTA) Ending Cash Position : kr103.93 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Ending Cash Position?

Cantargia AB's Ending Cash Position for the quarter that ended in Mar. 2025 was kr103.93 Mil.

Cantargia AB's quarterly Ending Cash Position declined from Sep. 2024 (kr59.81 Mil) to Dec. 2024 (kr33.04 Mil) but then increased from Dec. 2024 (kr33.04 Mil) to Mar. 2025 (kr103.93 Mil).

Cantargia AB's annual Ending Cash Position declined from Dec. 2022 (kr189.57 Mil) to Dec. 2023 (kr139.75 Mil) and declined from Dec. 2023 (kr139.75 Mil) to Dec. 2024 (kr33.04 Mil).

Cantargia AB Ending Cash Position Historical Data

The historical data trend for Cantargia AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Ending Cash Position Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 693.35 247.32 189.57 139.75 33.04

Cantargia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.60 84.69 59.81 33.04 103.93

Cantargia AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cantargia AB's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=139.747+-106.711
=33.04

Cantargia AB's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=33.037+70.895
=103.93

Cantargia AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Ending Cash Position
Comparable Companies
OSTO:ONCO OSTO:INIT OSTO:IRLAB A OSTO:IVACC XSAT:CESSA OSTO:LIPUM OSTO:ISOFOL OSTO:ACE OSTO:XBRANE OSTO:XINT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
7V3:Germany
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Website
https://www.cantargia.com
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines